Novartis AG Stock London S.E.

Equities

0QM7

CH0038459415

Pharmaceuticals

Delayed London S.E. 11:59:30 2018-05-21 am EDT 5-day change 1st Jan Change
76.86 CHF -1.00% Intraday chart for Novartis AG -0.77% -.--%
Sales 2024 * 49.29B 43.76B Sales 2025 * 51.41B 45.64B Capitalization 225B 200B
Net income 2024 * 10.99B 9.76B Net income 2025 * 12.22B 10.85B EV / Sales 2024 * 4.84 x
Net Debt 2024 * 13.22B 11.74B Net Debt 2025 * 11.6B 10.3B EV / Sales 2025 * 4.61 x
P/E ratio 2024 *
21.4 x
P/E ratio 2025 *
18.5 x
Employees -
Yield 2024 *
3.36%
Yield 2025 *
3.48%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
110.4 USD
Average target price
112.7 USD
Spread / Average Target
+2.06%
Consensus